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INTRODUCTION
I mmunoglobulin G4-related ophthalmic disease (IgG4-ROD) is characterized by enlargement of orbital tissues, infiltration of IgG4-positive plasma cells, and elevated serum IgG4 levels. The Japanese IgG4-related Ophthalmic Disease Study Group further revealed that the prevalence of IgG4-ROD among the orbital lymphoproliferative disorders was 22% [1] . IgG4-ROD can be found within the spectrum of systemic IgG4-related diseases (IgG4-RD) involving various systemic organs such as not only the orbit, but also pancreas, hepatobiliary tract, lung, kidney, retroperitoneum, and lymph nodes [2] [3] [4] [5] [6] . Systemic administration of corticosteroid is effective, and many patients have a good response to prednisolone (PSL) [5, 7] . Although the inflammation recurs while PSL was tapered in selected patients [5, 7] , the mechanisms underlying the recurrence and risk factors remain unknown. Furthermore, there are no studies elucidating the relationship between pathological findings and clinical courses. In this study, we investigated the clinicopathological features of IgG4-ROD, and analyzed the recurrence rates following systemic corticosteroid administration.
SUBJECTS AND METHODS
This was a retrospective observational study. Institutional Review Board of Hokkaido University Hospital for clinical research approved this study (IRB number: 011-0319). Patients with IgG4-ROD treated in Hokkaido University Hospital from February 2006 to December 2014 were enrolled in this study. This study retrospectively investigated clinical features, laboratory and histological findings based on the medical records of 21 patients. Inclusion criteria were that the enlargements of orbital tissues were surgically resected, and that the patients followed the diagnostic criteria of IgG4-ROD published in 2015 [2] . Briefly, the criteria included enlargement of tissues, high IgG4-positive plasma cell infiltration in the tissues (ratio of IgG4-positive cells to IgG-positive cells of 40% or above, or more than 50 IgG4-positive cells per highpower field with magnification of 400×), and elevated serum IgG4 concentration (≥135 mg/dL). Diagnoses were classified as 'definitive' when all of them were satisfied, 'probable' when enlargement of tissues and histopathologic criteria were satisfied, and 'possible' when enlargement of tissues and elevated serum IgG4 concentration were satisfied [2] . Patients with Sjögren syndrome, malignant lymphoma, sarcoidosis, Wegener granulomatosis, thyroid-related orbitopathy, idiopathic orbital inflammation, and dacryoadenitis or orbital cellulitis caused by bacteria or fungi infection were excluded in this study (UMIN registration number: R000033834). Informed consent was obtained from the patients according to the IRB recommendation. This study examined the clinical course and pathological differences in the excised orbital tissues between the patients with and without recurrence following systemic corticosteroid therapy. The patients were evaluated as recurrence when the organs enlarged again. Pathological Evaluation Twenty patients underwent surgical resection of tissues in the lacrimal gland enlargements and one patient underwent surgical resection of the nodule in the palpebral conjunctiva. The isolated tissues were fixed in formalin, and embedded in paraffin. Sections were submitted for hematoxylin and eosin staining and immunohistochemistry with anti-IgG4 and IgG antibodies to make histological diagnoses based on the IgG4-ROD diagnostic criteria. To evaluate the pathological difference between patients with and without recurrence following corticosteroid treatments, we analyzed IgG4:IgG ratio in infiltrating plasma cells, and the presence of fibrosis and lymphoid follicles in the excised tissues. As shown in Figure 1 , this study defined 'fibrosispositive' when fibrosis occupied 30% or over of the tissues under a low power field (magnification: 40×) ( Figure 1A ). Further this study defined 'lymphoid follicle-positive' ( Figure  1C , arrows), when we observed at least one clearly configured lymphoid follicle in each section. If not, the cases were evaluated as fibrosis and/or lymphoid follicle-negative ( Figure  1B, 1D Mean age of the onset in all the patients was 61y, and those of males and females were 67y (range 56-80) and 58y (range 36-78), respectively. The mean presumed clinical symptom duration of the disease was 12mo (2-91mo). Serum IgG4 levels elevated more than 135 mg/dL in 20 patients (95%). Mean serum IgG4 concentration was 658.2 mg/dL. Fourteen patients were diagnosed as definitive, 2 patients probable, and 5 patients possible IgG4-ROD. Sixteen patients (76%) had bilateral periocular involvements. Eyelid swelling was an initial symptom in 11 patients (52%) who did not show systemic involvements at a diagnosis. Ten patients (48%) had extraorbital involvements such as submandibular and parotid gland swelling (6 patients, 29%), lymphadenopathy (4 patients, 19%), and autoimmune pancreatitis (1 patient, 5%). Six patients (29%) had a medical history of bronchial asthma. Treatments Among 21 patients, 15 patients received systemic corticosteroid administration. Case 1 received steroid pulse therapy (methylprednisolone at 1 g per day for 3d, followed by PSL at 40 mg per day, with tapering thereafter) because of deteriorated visual acuity caused by retrobulber optic perineuritis. Oral PSL was administered to 14 patients (Cases 2-15). The initial dose of PSL was 30 mg or 40 mg per day, which was gradually tapered. Cases 17 and 18 were given topical corticosteroid treatment including nasal and inhaled corticosteroid by an otolaryngologist and a physician, because they have allergic rhinitis and bronchial asthma, respectively. We defined 'fibrosis-negative' when fibrosis occupied less than 30% of a low power field (hematoxylin and eosin, magnification: 40×); C: We defined 'lymphoid follicle-positive', when at least one clearly configured lymphoid follicle (arrows) was observed in a whole field (hematoxylin and eosin, magnification: 40×); D: We defined 'lymphoid follicle-negative', when any lymphoid follicle was not observed in a whole field (hematoxylin and eosin, magnification: 40×). Scale bar=100 μm.
A clinicopathological study on IgG4-ROD (Table 3 ).
All clinicopathological factors such as age, gender, laterality, systemic involvement, serum IgG4 levels, duration of the disease, and serum IgG4:IgG ratio, lymphoid follicles and fibrosis in the tissues, and diagnostic classification (definitive, probable or possible) were not associated with the recurrence. DISCUSSION IgG4-RD is a collection of disorders with unknown etiology that are characterized by an infiltrate of IgG4-immunopositive plasma cells accompanied by enlargement of various organs in the body. IgG4-ROD is characterized by enlargement of orbital and periocular tissues, including the lacrimal glands, extraocular muscles, infraorbital and supraorbital nerves, sclera and lacrimal sac [8] [9] [10] [11] . IgG4-ROD can be found in a part of IgG4-RD involving systemic organs [2] [3] [4] [5] [6] , which is commonly associated with bronchial asthma and allergic rhinitis [12] . In this study, more than half of patients suffering from eyelid swelling showed no systemic involvements at a diagnosis, suggesting that periocular enlargement can be early manifestation in IgG4-RD. The mean age of IgG4-ROD in our series was 61y, concurrent with other studies within the range of 51-61y [5, [13] [14] [15] . Previous study reported that IgG4-RD has a male-gender predilection [16] , whereas Andrew et al [17] addressed that IgG4-ROD affected men and women equally. In this study, female patients were more predominant in IgG4-ROD examined. The optimal therapeutic strategy for IgG4-ROD has yet to be established. Because IgG4-ROD rarely manifests spontaneous remission without any treatment [18] , steroid therapy is often used as a primary therapy for IgG4-ROD [13] . Most patients show response to the systemic corticosteroid therapy; however, Yu et al [13] reported that 2 of 8 patients with IgG4-ROD had poor response to systemic corticosteroid. The recurrence rates after steroid therapy ranged from 18%-58% [7, [14] [15] 19] . In this study, all patients showed good response to steroid therapy and one-third of the patients eventually recurred following the treatment.
There are some previous reports investigating the risk factors of relapse after systemic corticosteroid administration. Recent study reported that the extraophthalmic involvement is a risk factor for frequent orbital relapse after corticosteroid treatment [14] . Another study reported the incidence of patients who were positive for rheumatoid factor before corticosteroid treatment was higher in the recurrence group [19] . In this study, the presence of systemic involvement was not related to the recurrence, and the serum rheumatoid factor levels were not available, the latter of which are future issues to be resolved. To our knowledge, there are no studies elucidating the correlation between histological findings and activity of the disease in IgG4-ROD. In this study, the histological findings on lymphoid follicle and fibrosis were different in each patient. Therefore, we focused on the relationship between the histological findings and the clinical course of IgG4-ROD patients treated with systemic corticosteroids. However, there was no significant difference in the presence of lymphoid follicles and the extent of fibrosis between patients with or without recurrence. Further pathological studies are needed to elucidate the factors associated with recurrence after systemic corticosteroid administration. We observed female patients more frequently in IgG4-ROD. Moreover, this study demonstrated that many of them were postmenopausal females. Recently, Jiang et al [20] reported that estrogen and its receptor might inhibit inflammation in the rat tissues, suggesting that estrogen may become a new therapeutic target for inflammatory diseases. Therefore, we speculate one of reasons why female patients were more observed in this study might be decreased estrogen levels in post-menopause, facilitating development of orbital inflammation. Further studies are needed to examine the expression of estrogen receptor in IgG4-ROD tissues to prove estrogen in the regulation of inflammation as a first step.
Serial changes in serum IgG4 levels are reported to reflect the activity of IgG4-RD [21] . Yu et al [13] reported that patients with poor response for systemic corticosteroid administration showed significantly lower serum IgG4 levels and IgG4:IgG ratio, suggesting that lower serum IgG4 levels reflected lower disease activity. In this study, all patients had good response to systemic corticosteroid regardless of serum IgG4 levels and serum IgG4:IgG ratio at an initial presentation. In addition, there is no significant difference in serum IgG4 levels or serum IgG4:IgG ratio between the patients with or without recurrence. Therefore, serum IgG4 levels did not predict the response to steroid treatment for IgG4-ROD nor the recurrence after steroid treatment in this study.
There are limitations in this study. First, the number of patients who underwent surgical resections of enlarged orbital tissues is limited. Second, because this is a retrospective study, the treatment, the follow-up periods, and the amount of information about systemic diseases differed among patients. Third, since there is lack of standardized treatment protocol, it is difficult to identify factors associated with recurrence after systemic corticosteroid administration. Forth, significant differences in the lengths of the follow-up period also may let analyze difficult regarding factors associated with recurrence after systemic corticosteroid administration. Fifth, the most of biopsy specimens were collected by partial resection, which may not have reflected the pathology of entire lesions.
In conclusion, female patients might be more predominant in IgG4-ROD. Although inflammation recurred in one-third of patients, this study did not identify clinicopathological factors associated with recurrence after systemic corticosteroid administration.
